- Home
- BDRX vs BBLG Comparison
BDRX vs BBLG Comparison
Compare BDRX & BBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDRX | BBLG |
|---|---|---|
| Founded | 2000 | 2004 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6M | 1.2M |
| IPO Year | 2015 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BDRX | BBLG |
|---|---|---|
| Price | $0.68 | $0.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 7.6M | 54.5K |
| Earning Date | 09-12-2025 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $0.43 |
| 52 Week High | $11.88 | $2.89 |
Technical Indicators
Market Signals| Indicator | BDRX | BBLG |
|---|---|---|
| Relative Strength Index (RSI) | 36.88 | 23.89 |
| Support Level | $0.61 | N/A |
| Resistance Level | $1.58 | $0.59 |
| Average True Range (ATR) | 0.18 | 0.04 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 5.32 | 29.34 |
Price Performance
Historical ComparisonAbout BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About BBLG Bone Biologics Corp
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.